TQH2722

Primary objectives: 1. To evaluate the efficacy of TQH2722 injection in adult subjects with moderate to severe AD. Secondary objectives: 1. To evaluate the safety of TQH2722 injection in adult subjects with moderate to severe AD; 2. To evaluate the improvement of patient-reported outcomes (PROs) of TQH2722 injection in adult subjects with moderate to severe AD; 3. To evaluate the pharmacokinetic characteristics of TQH2722 injection in adult subjects with moderate to severe AD; 4. To evaluate the immunogenicity of TQH2722 injection in adult subjects with moderate to severe AD.